1 – 12 of 12
- show: 15
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=" "
width=" "
height=" "
allowtransparency="true"
frameborder="0">
</iframe>
- 2023
-
Mark
Urodrill - a novel MRI-guided endoscopic biopsy technique to sample and molecularly classify muscle-invasive bladder cancer without fractionating the specimen during transurethral resection
(
- Contribution to journal › Article
-
Mark
UROSCAN and UROSCANSEQ : a large-scale multicenter effort towards translation of molecular bladder cancer subtypes into clinical practice–from biobank to RNA-sequencing in real time
(
- Contribution to journal › Article
-
Mark
Tumor Biomarkers for Bacillus Calmette-Guérin Response : What We Get Is Not What We Want
(
- Contribution to journal › Debate/Note/Editorial
- 2022
-
Mark
Different Responses to Neoadjuvant Chemotherapy in Urothelial Carcinoma Molecular Subtypes
(
- Contribution to journal › Article
-
Mark
Molecular Subtypes as a Basis for Stratified Use of Neoadjuvant Chemotherapy for Muscle-Invasive Bladder Cancer—A Narrative Review
(
- Contribution to journal › Scientific review
- 2020
-
Mark
Re : A. Gordon Robertson, Clarice S. Groeneveld, Brian Jordan, et al. Identification of Differential Tumor Subtypes of T1 Bladder Cancer. Eur Urol. In press. http://doi.org/10.1016/j.eururo.2020.06.048
(
- Contribution to journal › Letter
- 2019
-
Mark
Re : Tuan Zea Tan, Mathieu Rouanne, Kien Thiam Tan, Ruby Yun-Ju Huang, Jean-Paul Thiery. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors. Eur Urol 2019;75:423–32
(
- Contribution to journal › Letter
-
Mark
Molecular subtypes applied to a population-based modern cystectomy series do not predict cancer-specific survival
(
- Contribution to journal › Article
- 2018
-
Mark
Molecular subtype classification of urothelial carcinoma in Lynch syndrome
(
- Contribution to journal › Article
- 2017
-
Mark
Re : Thomas Powles, Robert A. Huddart, Tony Elliott, et al. Phase III, Double-blind, Randomized Trial that Compared Maintenance Lapatinib versus Placebo after First-line Chemotherapy in Patients with Human Epidermal Growth Factor Receptor 1/2-positive Metastatic Bladder Cancer. J Clin Oncol 2017;35:48-55. Knowing HER2 Status is Not Enough: A Molecular Subtype Approach to Bladder
(
- Contribution to journal › Debate/Note/Editorial
- 2015
-
Mark
A Molecular Pathologic Framework for Risk Stratification of Stage T1 Urothelial Carcinoma.
(
- Contribution to journal › Article
-
Mark
On Molecular Classification of Bladder Cancer: Out of One, Many.
(
- Contribution to journal › Debate/Note/Editorial